Liofora (Drospirenone, Ethinylestradiol)

Drospirenone is a synthetic progestogen that binds to progesterone receptors, exerting anti‑mineralocorticoid and anti‑androgenic activity. In combination with ethinylestradiol, it suppresses the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), thereby preventing ovulation. It also thickens cervical mucus and alters the endometrium, reducing fertilisation and implantation.

The prescribed regimen for Liofora is determined by the treating clinician. Typically, the product is supplied as a tablet containing drospirenone 3 mg and ethinylestradiol 20 µg to be taken once daily for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule must be set by a qualified health‑care professional.

Liofora is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the product should be discontinued immediately. Limited data are available for use while breastfeeding; most guidelines advise avoiding combined oral contraceptives during lactation, especially in the early postpartum period, unless the benefits outweigh potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Liofora tablets. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation. The team coordinates delivery in compliance with international regulations.

Liofora contains drospirenone, which offers anti‑mineralocorticoid and anti‑androgenic properties that may result in a lower risk of water retention and acne compared with some other progestins. Efficacy in preventing pregnancy is comparable to other combined oral contraceptives, while the side‑effect profile may differ slightly, making it a suitable alternative for women seeking these specific hormonal characteristics.

Liofora tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep the product in its original blister pack or container, protect it from moisture and direct sunlight, and ensure that it is out of reach of children. Do not use tablets that have been exposed to excessive heat or humidity.

Liofora is taken orally, usually once each day at the same time, with or without food. The typical regimen consists of 21 consecutive active tablets followed by a 7‑day hormone‑free interval, during which withdrawal bleeding occurs. Patients should not miss doses and should follow the prescribing clinician’s instructions for any missed tablets to maintain contraceptive effectiveness.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or myocardial infarction), severe hypertension, liver disorders and gallbladder disease. These events are rare but can be life‑threatening. Women with a history of clotting disorders, smoking, age over 35, or certain medical conditions should be evaluated carefully before initiating therapy.

Liofora is contraindicated in women who are pregnant, have known or suspected thromboembolic disease, estrogen‑dependent tumors (such as certain breast cancers), uncontrolled hypertension, severe liver disease, or a history of stroke. It should also be avoided in women who are breastfeeding during the early postpartum period unless a risk‑benefit assessment supports use. Patients with known hypersensitivity to drospirenone, ethinylestradiol or any tablet excipients must not take the product.